Overview of the Analytes Applied in Genotypic HIV Drug Resistance Testing

Hezhao Ji; Paul Sandstrom

doi:10.3390/pathogens11070739

Overview of the Analytes Applied in Genotypic HIV Drug Resistance Testing

Pathogens. 2022 Jun 29;11(7):739. doi: 10.3390/pathogens11070739.

Authors

Hezhao Ji^{1

2}, Paul Sandstrom^{1

2}

Affiliations

¹ National Microbiology Laboratory at JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
² Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.

Abstract

The close monitoring of HIV drug resistance using genotypic HIV drug resistance testing (HIVDRT) has become essential for effective HIV/AIDS management at both individual and population levels. Over the years, a broad spectrum of analytes or specimens have been applied or attempted in HIVDRT; however, the suitability and performance of these analytes in HIVDRT and the clinical relevance of the results from them may vary significantly. This article provides a focused overview of the performance, strengths, and weaknesses of various analytes while used in HIVDRT, which may inform the optimal analytes selection in different application contexts.

Keywords: HIV; analytes; drug resistance; performance; specimens; testing.

Publication types

Review

Grants and funding

This research received no external funding.